Skip to main content

EDITORIAL article

Front. Pharmacol., 29 June 2022
Sec. Translational Pharmacology
This article is part of the Research Topic Hydrogen sulfide: Physiology, Pharmacology and Toxicology, Volume II View all 8 articles

Editorial: Hydrogen sulfide: Physiology, Pharmacology and Toxicology, Volume II

  • Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, China

Hydrogen sulfide (H2S) is a reducing gas molecule in mammalian cells that can be endogenously synthesized by several enzymes, including cystathione β-synthase (CBS), cystathione γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) (Sun et al., 2021). To date, a host of studies have revealed the great potential of H2S in preventing and treating a variety of human diseases by regulating numerous targets or signaling pathways (Rong et al., 2023). Despite our growing understanding of H2S-mediated biological and pharmacological effects on different systems, the precise underlying mechanisms responsible for the complicated effects of H2S have yet to be fully defined. As H2S is one of the important areas for the rapid development of gaseous signaling molecules, an overview of the results obtained in the past and future prospects may be highly desirable. To this end, we launched the Volume 2 of Hydrogen sulfide: Physiology, Pharmacology and Toxicology to highlight recent advances in our understanding of the physiological and pharmacological functions of H2S, including but not limited to biological function in the new compounds releasing H2S, polysulfide and SO2, new methods for detection of endogenous and exogenous H2S, advances in biosynthesis and metabolism of H2S, current understanding about protein sulfhydration, signaling mechanisms underlying the biological functions of H2S, prospect of sulfide-containing nature products and H2S synthesis inhibitors as therapeutic drugs. After the joint efforts of the journal, editors, reviewers, and contributors, a total of seven high-quality articles were received, including five original articles and 2 review articles. Although small in the kingdom of H2S, these seven articles have certainly contributed to advancing understanding of H2S biology and pharmacology. We have made a detailed summary and perspective for these seven articles as follows.

Hypothyroidism is characterized by the disruption of thyroid hormone synthesis and secretion by thyrocytes (Zhang et al., 2021). Sirtuin-1 (SIRT1) inactivation is involved in thyroid cell damage and thyroid hormone deficiency (Wei et al., 2022). H2S, as a gas signaling molecule, participates in many physiopathologic processes by upregulating SIRT1 (Yang et al., 2021). For this reason, Zhang’s group explored whether H2S promoted the synthesis and secretion of thyroid hormones by upregulating SIRT1 (Zhao et al.). It was found that serum levels of H2S were significantly downregulated in hypothyroid patients when compared to those of euthyroid participants (Zhao et al.). A H2S donor sodium hydrosulfide (NaHS) promoted thyroid function in hypothyroid rats and elevated the protein levels of TPO, NIS, Pendrin and MCT8 in human thyrocytes, an effect that was SIRT1-dependent, thus providing a new view of H2S for treating hypothyroidism (Zhao et al.). Through computer molecular docking technology, Geng’s group screened the natural small molecule compound norswertianolin (NW)-specific binding to CSE at Leu68 site (Niu et al.). Further studies disclosed that NW acting on the CSE/H2S system attenuated acute and long-term renal ischemia/reperfusion (I/R) injury, lowered blood pressure, ameliorated vascular remodeling and inflammation in rats (Niu et al.). Hence, NW may serve as a novel small molecular chemical compound CSE agonist, directly binding to CSE, heightening CSE generation–H2S activity, and then alleviating kidney I/R injury and hypertension (Niu et al.). In a study by Ni’s group, the authors identified that the arterial oxygen saturation (SaO2) was decreased in model of mouse with genetic deficiency of CSE, along with mild hypoxia occurred in the tissues of heart, lungs and kidneys in CSE−/− mice (Huang et al.). H2S donor GYY4137 treatment increased SaO2 and ameliorated hypoxia state in cardiac and renal tissues (Huang et al.). Besides, they found the alveolar wall thickening, diffuse interstitial edema and leukocyte infiltration in pulmonary tissues and the increased inflammation and oxidative stress in the lung tissues of CSE-deficient mice, which were all ameliorated by GYY4137 treatment (Huang et al.). This observation indicated that endogenous H2S is an important factor in maintaining normal SaO2 by preventing oxidative stress and inflammation in the lungs.

The use of cyclosporine A (CsA) in transplant recipients is limited due to its side effects of causing severe hypertension (Pandey et al., 2022). CsA is reported to increase the activity of the epithelial sodium channel (ENaC) in cultured distal nephron cells, a potential event involved in CsA-induced hypertension (Wu et al., 2019). With this in mind, Ma’s research group investigated whether ENaC mediates CsA-induced hypertension and H2S could prevent such a type of hypertension (Wang et al.). They found that the open probability of epithelial sodium channel (ENaC) in principal cells of split-open cortical collecting ducts was significantly increased in rats after treatment with cyclosporine A (CsA), coinciding with intracellular reactive oxygen species (ROS) overproduction, such elevations were completely reversed by lovastatin (an inhibitor of cholesterol synthesis) or NaHS (a donor of H2S) (Wang et al.). Thereby, NaHS ameliorates CsA-induced hypertension by inhibition of oxidative stress (Wang et al.). In the cardiovascular system, endogenous H2S can lead to both vasodilatation and vasoconstriction (Mitidieri et al., 2021). Several mechanisms mediate vasodilatation induced by addition of exogenous H2S salts, including lowering of smooth muscle cells calcium by activation of K channels, enhancement of nitric oxide (NO) signaling, and changes in intracellular pH by inhibition of an acid-sensitive Cl2/HCO3-exchanger, to name a few (Meng et al., 2015). Abramavicius et al. tested the mechanisms involved in relaxation of small arteries induced by GYY4137. In pre-contracted small mesenteric arteries, GYY4137 induced concentration-dependent relaxations, which were inhibited by l-cysteine, blockers of large-conductance calcium-activated (BKCa) and voltage-gated type 7 (KV7) potassium channels (Abramavicius et al.). The perspective is that the rate of release of sulfides plays an important role for the effects of H2S salt vs. donors in small arteries, and hence for a beneficial effect of GYY4137 for treatment of cardiovascular disease.

My laboratory contributed a review article regarding the roles and molecular mechanism of H2S in cardiomyopathy and myocardial I/R injury under diabetes (Sun et al.). In this review article, we summarized the current findings on H2S biology and pharmacology, especially focusing on the novel mechanisms of H2S-based protection against diabetic cardiomyopathy and diabetes-aggravated cardiac I/R injury (Sun et al.). Li’s group reviewed the role of H2S in bone metabolism, and they summarized the current information about H2S donors related to bone metabolism diseases, such as osteoporosis and osteoarthritis, and discussed some mechanisms and biological applications (Hao et al.). Thus, H2S may be a novel regulator in bone metabolism (Hao et al.). Overall, these seven articles collected in this Research Topic highlighted the therapeutic potential of H2S in hypothyroidism, renal injury, vasodilation dysfunction, hypertensive vascular remodeling, lung inflammation, CsA-induced hypertension, diabetic cardiomyopathy, and bone disorders. H2S is considered an essential signaling molecule in the cardiovascular and nervous systems and a variety of pathophysiological changes. Despite the huge clinical value of H2S, we should be cautious while we are excited, especially considering the tissue specificity of H2S-producing enzymes, inconsistent and conflicting results of H2S, lower bioavailability, side effects, and even toxicity of H2S donors, lack of clinical practice on H2S. There is no doubt that the development of effective and long-lasting H2S donors is crucial for understanding the biological and pharmaceutical functions of H2S in various systems. We look forward to generating more interesting research in this area, and rapid clinical translation of H2S.

Author Contributions

J-SB drafted and reviewed the manuscript, and approved the submitted version.

Funding

This work was supported by Ministry of Education of Singapore Tier 2 Research grant (MOE2017-T2-2-029), and Jiangsu Nature Science Foundation (BK20181185).

Conflict of Interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Meng, G., Ma, Y., Xie, L., Ferro, A., and Ji, Y. (2015). Emerging Role of Hydrogen Sulfide in Hypertension and Related Cardiovascular Diseases. Br. J. Pharmacol. 172, 5501–5511. doi:10.1111/bph.12900

PubMed Abstract | CrossRef Full Text | Google Scholar

Mitidieri, E., Vellecco, V., Brancaleone, V., Vanacore, D., Manzo, O. L., Martin, E., et al. (2021). Involvement of 3',5'-cyclic Inosine Monophosphate in Cystathionine γ-lyase-dependent Regulation of the Vascular Tone. Br. J. Pharmacol. 178, 3765–3782. doi:10.1111/bph.15516

PubMed Abstract | CrossRef Full Text | Google Scholar

Pandey, S., Tripathi, P., Gupta, A., and Yadav, J. S. (2022). A Comprehensive Review on Possibilities of Treating Psoriasis Using Dermal Cyclosporine. Drug Deliv. Transl. Res. 12, 1541–1555. doi:10.1007/s13346-021-01059-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Rong, F., Wang, T., Zhou, Q., Peng, H., Yang, J., Fan, Q., et al. (2023). Intelligent Polymeric Hydrogen Sulfide Delivery Systems for Therapeutic Applications. Bioact. Mater. 19, 198–216. doi:10.1016/j.bioactmat.2022.03.043

PubMed Abstract | CrossRef Full Text | Google Scholar

Sun, H. J., Wu, Z. Y., Nie, X. W., Wang, X. Y., and Bian, J. S. (2021). Implications of Hydrogen Sulfide in Liver Pathophysiology: Mechanistic Insights and Therapeutic Potential. J. Adv. Res. 27, 127–135. doi:10.1016/j.jare.2020.05.010

PubMed Abstract | CrossRef Full Text | Google Scholar

Wei, X., Tan, J., and Gao, H. (2022). Role of Sirtuin 1 in the Brain Development in Congenital Hypothyroidism Rats via the Regulation of P53 Signaling Pathway. Bioengineered 13, 9455–9466. doi:10.1080/21655979.2022.2060626

PubMed Abstract | CrossRef Full Text | Google Scholar

Wu, M. M., Liang, C., Yu, X. D., Song, B. L., Yue, Q., Zhai, Y. J., et al. (2019). Lovastatin Attenuates Hypertension Induced by Renal Tubule-specific Knockout of ATP-Binding Cassette Transporter A1, by Inhibiting Epithelial Sodium Channels. Br. J. Pharmacol. 176, 3695–3711. doi:10.1111/bph.14775

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, L., Li, D. X., Cao, B. Q., Liu, S. J., Xu, D. H., and Zhu, X. Y. (2021). Exercise Training Ameliorates Early Diabetic Kidney Injury by Regulating the H(2) S/SIRT1/p53 Pathway. FASEB J. 35, e21823. doi:10.1096/fj.202100219r

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, X., Kellogg, A. P., Citterio, C. E., Zhang, H., Larkin, D., Morishita, Y., et al. (2021). Thyroid Hormone Synthesis Continues Despite Biallelic Thyroglobulin Mutation with Cell Death. JCI Insight 6, e148496. doi:10.1172/jci.insight.148496

CrossRef Full Text | Google Scholar

Keywords: hydrogen sulfide, pharmacology, biology, cardiovascular, toxicology—metabolism, physiology

Citation: Bian J-S (2022) Editorial: Hydrogen sulfide: Physiology, Pharmacology and Toxicology, Volume II. Front. Pharmacol. 13:943101. doi: 10.3389/fphar.2022.943101

Received: 13 May 2022; Accepted: 31 May 2022;
Published: 29 June 2022.

Edited and reviewed by:

Alastair George Stewart, The University of Melbourne, Australia

Copyright © 2022 Bian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jin-Song Bian, bianjs@sustech.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.